OMEGA FUND MANAGEMENT LLC
Q3 2026 Form 13-F

BOSTON, MASSACHUSETTS
CIK 0001637359 · CRD 157753 · SEC-registered investment adviser
$125.2M Reported Value Total

OMEGA FUND MANAGEMENT, LLC reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $1,713,751,848, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
9 funds · $927.5M gross asset value
Venture Capital Fund: $806.5M · Private Equity Fund: $121.1M
Source: Form ADV filed 2026-03-26
Reported value
$125.2M
Quarter over quarter
-14.5%
Holdings
10
Top-10 concentration
100.0%

Key People

Form ADV owners & control persons
Otello (nmn) Stampacchia
MEMBER AND MANAGER
Francesco Luigi Draetta
MANAGER & MEMBER
Claudio Pier Antonio Nessi
MANAGER & MEMBER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $125.2M
Positions 10
Change in reported value -32.6%
New positions 1
Exited positions 1
Position turnover 18.2%
Top-10 concentration 100.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
10 $125.2M
Q2 2026 13F
Filed Aug 14, 2026
10 $185.7M
Q1 2026 13F
Filed May 15, 2026
10 $163.1M
Q4 2025 13F
Filed Feb 17, 2026
11 $286.5M
Q3 2025 13F
Filed Nov 14, 2025
12 $222.4M
Q2 2025 13F
Filed Aug 14, 2025
13 $154.4M
Q1 2025 13F
Filed May 15, 2025
13 $169.5M
Q4 2024 13F
Filed Feb 14, 2025
12 $154.2M
Q3 2024 13F
Filed Nov 14, 2024
11 $160.0M
Q2 2024 13F
Filed Aug 14, 2024
11 $135.0M
Q1 2024 13F
Filed May 14, 2024
11 $155.0M
Q4 2023 13F
Filed Feb 14, 2024
14 $123.4M
Q3 2023 13F
Filed Nov 14, 2023
12 $108.9M
Q2 2023 13F
Filed Aug 14, 2023
12 $178.5M
Q1 2023 13F
Filed May 15, 2023
14 $153.3M
Q4 2022 13F
Filed Feb 13, 2023
16 $296.7M
Q3 2022 13F
Filed Nov 14, 2022
19 $273.1M
Q2 2022 13F
Filed Aug 15, 2022
21 $313.3M
Q1 2022 13F
Filed May 13, 2022
22 $488.6M
Q4 2021 13F
Filed Feb 14, 2022
22 $707.3M

28 earlier quarters on file — choose one from the quarter menu above.

Top 10 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 NUVB Nuvation Bio Inc. $40.0M 31.99%
2 BCAX Bicara Therapeutics Inc. $32.8M 26.17%
3 BBNX Beta Bionics Inc. $18.3M 14.59%
4 BBOT BridgeBio Oncology Therapeutics Inc. $13.5M 10.78%
5 KMTS Kestra Med Technologies Ltd $10.3M 8.19%
6 IMUX Immunic, Inc. $4.0M 3.2%
7 SANA Sana Biotechnology, Inc. $2.5M 1.97%
8 IMA ImageneBio, Inc. $2.1M 1.67%
9 ENGN enGene Holdings Inc. $1.8M 1.4%
10 ODTX Odyssey Therapeutics Inc. $64.3K 0.05%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings